Clinical predictors of depressive symptom remission and response after racemic ketamine and esketamine infusion in treatment‐resistant depression
A. P. Jesus-Nunes, G. C. Leal, F. S. Correia-Melo, F. Vieira, R. Mello, A. T. Caliman-Fontes, Mariana V F Echegaray, R. Marback, Lívia N F Guerreiro-Costa, B. Souza-Marques, C. Santos-Lima, Lucca S. Souza, I. D. Bandeira, F. Kapczinski, A. Lacerda, L. Quarantini
Human Psychopharmacology February 18, 2022 DOI: 10.1002/hup.2836 (opens in new tab) via Semantic Scholar
Summary
AI-generated from the abstractMost people with major depressive disorder do not achieve symptom remission, and treatment-resistant depression is defined by the failure of at least one adequate antidepressant trial. This study investigated clinical predictors of depressive symptom remission and response 24 hours and 7 days after infusions of racemic ketamine and esketamine.
Study at a glance
| Characteristics | Observational cohort Peer reviewed |
|---|---|
| Population | People with treatment-resistant depression |
| Interventions | Racemic ketamine Esketamine |
| Duration | 24 hours and 7 days after infusion |
| Keywords | Medicine Psychology |
| Citations | 39 |
| Key finding | Clinical predictors of depressive symptom remission and response were identified 24 hours and 7 days after racemic ketamine and esketamine infusions. |
Abstract
Major depressive disorder (MDD) is a leading cause of disability worldwide and most people do not achieve symptom remission. Treatment‐resistant depression (TRD) is characterized by the failure of at least one adequate trial of a major class of antidepressant, with adequate time and dosage. We aimed to identify clinical predictors of depressive symptom remission and response 24 h and 7 days after racemic ketamine and esketamine infusions.